Trials / Withdrawn
WithdrawnNCT03033862
Thrombogenicity Assessment in Patients Treated With Bioresorbable Vascular Scaffolds
- Status
- Withdrawn
- Phase
- —
- Study type
- Observational
- Enrollment
- 0 (actual)
- Sponsor
- Inova Health Care Services · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Platelet activation and aggregation, intrinsic thrombogenicity, and biomarkers (fibrinogen, C-reactive protein, platelet endothelial cell adhesion molecule, von Willebrand factor, p-selectin) will be measured and compared following the implantation of Bioreabsorbable Vascular Scaffolds and Drug Eluting Stents.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Bioresorbable Vascular Scaffold | Bioresorbable Vascular Scaffold |
| DEVICE | Drug Eluting Stent | Drug Eluting Stent |
Timeline
- Start date
- 2017-07-01
- Primary completion
- 2017-07-01
- Completion
- 2017-07-01
- First posted
- 2017-01-27
- Last updated
- 2020-06-16
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT03033862. Inclusion in this directory is not an endorsement.